Outlook Therapeutics (OTLK) Cash from Operations (2015 - 2026)
Outlook Therapeutics (OTLK) reported Cash from Operations of 7828055.0 for Q1 2026, up 52.8% year-over-year from 5123179.17 in Q1 2025, and up 47.6% quarter-over-quarter from 14939111.0 in Q4 2025.
Outlook Therapeutics (OTLK) Cash from Operations (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Cash from Operations data on file, last reported at 7828055.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 7828055.0, up 52.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 47045522.0 (up 26.54% YoY), and the FY2025 annual result was 51829437.0, up 24.66% from the prior year.
- Cash from Operations improved to 7828055.0 in Q1 2026 per OTLK's latest filing, from 14939111.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 7828055.0 in Q1 2026 and troughed at 21099242.0 in Q2 2022.
- A 5-year average of 13649891.76 and a median of 13032169.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations slumped 137.44% in 2024, then jumped 52.8% in 2026.
- A 5-year view of Cash from Operations shows it stood at 8901246.0 in 2022, then plunged by 46.41% to 13032169.0 in 2023, then climbed by 15.84% to 10967335.0 in 2024, then slumped by 36.21% to 14939111.0 in 2025, then jumped by 47.6% to 7828055.0 in 2026.
- Business Quant data shows OTLK's Cash from Operations at 7828055.0 in Q1 2026, 14939111.0 in Q4 2025, and 12377197.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -7.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.83 Mn |
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Dec 31, 2023 | -13.03 Mn |
| Dec 31, 2023 | -13.03 Mn |